文献速递心力衰竭与心肌病心律失常瓣膜病与结构性心脏病

日本肥厚型心肌病全国前瞻性注册研究基线特征与管理模式

Contemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registry.
PubMed 文献 · Heart · 2025-08-26

中位注册年龄69岁、诊断年龄60岁,男性54%,家族性18%,梗阻性36%,房颤27%。β阻滞剂用于90%梗阻性患者,51%用西苯唑啉,22%接受室间隔减容治疗,6%外科心肌切除。

要点

  • 梗阻性HCM占36%,β阻滞剂使用率90%,西苯唑啉51%。
  • 房颤占27%,既往室速/室颤6%,心衰住院11%,栓塞事件5%。
  • 除颤器植入11%,不同指南I类/IIa类推荐比例差异明显。

核心结论

  • 作为日本首个大规模前瞻性HCM注册研究,提供了HCM临床特征与管理的基线数据,有助于缩小实践与指南推荐之间的差距。

主要发现

  • 注册中位年龄69岁,诊断中位年龄60岁,男性占54%,家族性HCM确认占18%。
  • 梗阻性HCM占36%,中段室性梗阻占8%,心尖部HCM占14%,终末期占4%。
  • 房颤占27%,既往持续性室速或室颤占6%,需住院的心衰占11%,栓塞事件占5%。
  • 除颤器植入占11%;日本指南IIa类推荐占全队列22%、植入患者中19%,欧洲指南分别为4%和39%,美国指南分别为28%和22%。
  • 梗阻性HCM中β阻滞剂处方占90%,西苯唑啉占51%,室间隔减容治疗占22%,其中外科心肌切除占6%。

关键数值与推荐

  • 梗阻性HCM定义为本队列中36%的患者,中段室性梗阻占8%,心尖部HCM占14%,终末期占4%。
  • 家族性HCM确认占18%,房颤占27%,既往持续性室速或室颤占6%,心衰住院占11%,栓塞事件占5%。
  • 除颤器植入占11%;日本指南IIa类推荐在全队列占22%、植入患者中占19%,欧洲指南为4%和39%,美国指南为28%和22%。
  • 梗阻性HCM中β阻滞剂占90%,西苯唑啉占51%,室间隔减容治疗占22%,外科心肌切除占6%。

临床怎么用

  • 日本真实世界数据显示梗阻性HCM中β阻滞剂使用率高达90%,西苯唑啉使用率51%,室间隔减容治疗22%。
  • 房颤(27%)与心衰住院(11%)常见,提示需关注HCM患者房颤筛查与心衰管理。
  • 除颤器植入率11%,但不同指南IIa类推荐比例差异大,提示需按指南评估一级预防指征。

局限性

  • 本分析仅报告基线入组数据,未提供随访结局。
  • 研究来自24家转诊医院,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Japanese Hypertrophic Cardiomyopathy Registry Study was designed to provide comprehensive, real-world insights into the clinical characteristics and management of hypertrophic cardiomyopathy (HCM) in Japan. METHODS: This multicentre, prospective study enrolled consecutive patients with HCM from 24 referral hospitals across Japan starting in 2016. The baseline characteristics of 1485 patients enrolled by December 2019 are presented in this analysis. RESULTS: The median ages at registration and diagnosis were 69 and 60 years, respectively, with men accounting for 54% of the cohort. Familial HCM was confirmed in 18% of cases. Of the cohort, 36% had hypertrophic obstructive cardiomyopathy (HOCM), while 8% had mid-ventricular obstruction, 14% had apical HCM and 4% were in the end-stage phase. Atrial fibrillation was observed in 27% of patients, though the majority were asymptomatic or had mild symptoms at registration. Adverse outcomes included prior sustained ventricular tachycardia or fibrillation (6%), heart failure requiring hospitalisation (11%) and embolic events (5%). Defibrillator implantation was performed in 11% of patients. Differences in the defibrillator indications for primary prevention in the current three guidelines and status of defibrillator deployment at registration were clarified: the percentages of class IIa recommendation in the whole cohort and of patients with defibrillator implantation in class IIa were 22% and 19% in the Japanese guidelines, 4% and 39% in the European guidelines and 28% and 22% in the American guidelines, respectively. Beta blockers were prescribed to 90% of patients with HOCM, while 51% received cibenzoline. Septal reduction therapies were performed in 22% of patients with HOCM, with 6% undergoing surgical myectomy. CONCLUSIONS: As the first large-scale, prospective HCM registry in Japan, this study provides valuable baseline data on the clinical characteristics and management of HCM. These findings will help address gaps between current practice and guideline recommendations, improving the care of patients with HCM.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Kubo T, Sugiura K, Tokita Y, et al. Contemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registry. Heart. 2025. PMID: 40037766. doi:10.1136/heartjnl-2024-324811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。